Cleveland Diagnostics, Inc. is a clinical-stage biotechnology company that focuses on developing next-generation innovative diagnostic tests for the early detection of various diseases, with a particular emphasis on cancer.Cleveland Diagnostics introduces a new category of straightforward blood tests designed to detect the presence or absence of diseases. Their flagship product, IsoPSA, addresses the urgent need for a more concise method to help avoid unnecessary prostate biopsies. Leveraging its unique SIA-based technology platform, Cleveland Diagnostics aims to transform cancer diagnosis into a less daunting prospect. The company facilitates prompt and potentially lifesaving medical decisions by providing physicians and patients with more accurate cancer insights at earlier stages.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/17/2024 | Series E-2 | $26.99MM | $xx.xx | $289.79MM | Novo Holdings | |
Price per Share
$xx.xx
Shares Outstanding
5,408,160
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Novo Holdings
|
||||||
01/17/2024 | Series E-1 | $43.75MM | $xx.xx | $289.79MM | Novo Holdings | |
Price per Share
$xx.xx
Shares Outstanding
8,765,603
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Novo Holdings
|
||||||
02/09/2021 | Series D | $17.4MM | $xx.xx | $155.87MM | LYFE Capital, Cleveland Clinic | |
Price per Share
$xx.xx
Shares Outstanding
3,763,301
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.1x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
LYFE Capital, Cleveland Clinic
|
||||||
11/27/2017 | Series C | $10.61MM | $xx.xx | $107.6MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,505,532
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
11/16/2016 | Series B | $2.29MM | $xx.xx | $30.16MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,459,271
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
03/03/2015 | Series A | $1.98MM | $xx.xx | $13.2MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,385,244
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|